Citigroup
BOLD

Citigroup’s Audentes Therapeutics, Inc BOLD Stock Holding History

Citigroup’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-53,035
Closed -$3.17M – 7961
2019
Q4 		$3.17M Sell
53,035
-652
-1% -$24.5K ﹤0.01% 2484
2019
Q3 		$1.51M Buy
53,687
+4,862
+10% +$166K ﹤0.01% 3175
2019
Q2 		$1.85M Buy
48,825
+34,651
+244% +$1.33M ﹤0.01% 2952
2019
Q1 		$553K Sell
14,174
-94,605
-87% -$2.71M ﹤0.01% 4077
2018
Q4 		$2.32M Buy
108,779
+76,789
+240% +$1.98M ﹤0.01% 2535
2018
Q3 		$1.27M Buy
31,990
+28
+0.1% +$1.04K ﹤0.01% 3224
2018
Q2 		$1.22M Sell
31,962
-4,279
-12% -$158K ﹤0.01% 3142
2018
Q1 		$1.09M Buy
36,241
+8,977
+33% +$304K ﹤0.01% 3162
2017
Q4 		$852K Buy
27,264
+26,273
+2,651% +$721K ﹤0.01% 3510
2017
Q3 		$28K Buy
991
+889
+872% +$19.3K ﹤0.01% 6305
2017
Q2 		$2K Sell
102
-51
-33% -$815 ﹤0.01% 7076
2017
Q1 		$3K Buy
153
+149
+3,725% +$2.41K ﹤0.01% 6965
2016
Q4 		$0 Sell
4
-465
-99% -$8.03K ﹤0.01% 7403
2016
Q3 		$8K Buy
+469
New +$7.12K ﹤0.01% 6641

Citigroup's BOLD Position: Q1 2020 in Review

Citigroup sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 53,035 shares — an estimated $3.17M sold.

Citigroup first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $3.17M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • Citigroup reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Citigroup sold 53,035 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $3.17M.
  • Citigroup first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
  • Citigroup's Audentes Therapeutics, Inc position peaked at $3.17M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.